Abstract
The mechanisms by which oligodendroglia modulate CNS angiogenesis remain elusive. Previous in vitro data suggest that oligodendroglia regulate CNS endothelial cell proliferation and blood vessel formation through hypoxia inducible factor alpha (HIFα)-activated Wnt (but not VEGF) signaling. Using in vivo genetic models, we show that HIFα in oligodendroglia is necessary and sufficient for angiogenesis independent of CNS regions. At the molecular level, HIFα stabilization in oligodendroglia does not perturb Wnt signaling but rather activates VEGF. At the functional level, genetically blocking oligodendroglia-derived VEGF but not Wnt significantly decreases oligodendroglial HIFα-regulated CNS angiogenesis. Blocking astroglia-derived Wnt signaling reduces astroglial HIFα-regulated CNS angiogenesis. Together, our in vivo data demonstrate that oligodendroglial HIFα regulates CNS angiogenesis through Wnt-independent and VEGF-dependent signaling. These findings suggest an alternative mechanistic understanding of CNS angiogenesis by postnatal glial cells and unveil a glial cell type-dependent HIFα-Wnt axis in regulating CNS vessel formation.
Subject terms: Developmental biology, Angiogenesis, Developmental neurogenesis
In the central nervous system, the maturation of glial cells is temporally and functionally coupled with that of the vascular network during postnatal development. Here the authors show that oligodendroglial HIFα regulates CNS angiogenesis through Wnt-independent and VEGF-dependent signaling, while astroglial HIFα participates through Wnt-dependent signaling.
Introduction
The vasculature of the central nervous system (CNS), which is developed exclusively through angiogenesis, plays a crucial role in providing neural cells with nutrients and oxygen. CNS angiogenesis, the growth of new blood vessels from pre-existing ones, starts during embryonic development and matures during postnatal development in human and rodent brains, for example, by the age of one month in rodents1. Dysregulated CNS angiogenesis negatively impacts postnatal brain development and functional recovery from brain injuries2–4. The current study aimed to dissect the molecular regulation of postnatal CNS angiogenesis using in vivo genetic animal models.
The developing CNS parenchyma is exposed to physiological hypoxia with local oxygen concentration ranging from 0.5 to 7%5. Hypoxia-inducible factor α (HIFα) is a critical regulator that adapts neural cells to hypoxic conditions. The transcription factor HIFα, including HIF1α and HIF2α, is subjected to constant degradation. Von Hippel-Lindau (VHL), a negative regulator of HIFα’s transcriptional activity, plays an essential role in HIFα degradation. Under low oxygen or upon VHL disruption, HIF1α and HIF2α degradation is impaired and subsequently translocate into the nuclei where they regulate downstream target genes through forming transcriptional active complexes with the constitutive HIF1β6,7. Previous data suggest that HIFα function in neural precursor cells is required for embryonic brain vascular development8. Recent data including those from our own laboratory show that HIFα function in oligodendroglial lineage cells may play a pivotal role in regulating postnatal angiogenesis in the brain white matter9 and in the spinal cord10. However, the molecular mechanisms underlying oligodendroglial HIFα-regulated angiogenesis are still controversial and remain incompletely defined.
The current concept stated that oligodendroglial HIFα promotes CNS angiogenesis through activating signaling pathway of Wnt but not vascular endothelial growth factor (VEGF)9. However, this “Wnt-dependent” view was supported only by in vitro studies and pharmacological manipulations9, in which “pathological” activation of Wnt signaling, poor cell-type selectivity and/or off-target effects of small compounds cannot be excluded. In this study, we present in vivo evidence supporting an alternative view in our mechanistic understanding of oligodendroglial HIFα-regulated CNS angiogenesis. Our in vivo genetic knockout data reveal that oligodendroglial HIFα regulates endothelial cell proliferation and angiogenesis in a VEGF-dependent but Wnt-independent manner and this regulation is independent of CNS regions during postnatal development. This data also demonstrate that postnatal astroglia regulate CNS angiogenesis at least in part through HIFα-activated Wnt signaling, unveiling a glial cell type-specific HIFα-Wnt connection in the CNS.
Results
Oligodendroglial HIFα regulates CNS angiogenesis
Endothelial cell (EC) proliferation is an essential step of angiogenesis and the blood vessel density is an end-point reflection of angiogenesis. Therefore, we used EC proliferation and vessel density as in vivo readouts of angiogenesis9. To quantify blood vessel density, we used the basement membrane marker Laminin to label blood vessels and employed a semi-automated approach to calculate the percentage of Laminin-occupying area among total assessed area (Supplementary Fig. 1). To determine whether oligodendroglial HIFα is required for angiogenesis throughout the postnatal CNS, Cre-LoxP approach was used to genetically ablate or stabilize HIFα and EC proliferation and vessel density were analyzed in the brain and the spinal cord.
We used Cnp-Cre line11 to generate Cnp-Cre:Hif1αfl/fl (HIF1α conditional knockout, cKO), Cnp-Cre: Hif2αfl/fl (HIF2α cKO), and Cnp-Cre: Hif1αfl/fl:Hif2αfl/fl (HIF1α/HIF2α or HIFα double cKO) mutants (Supplementary Fig. 2). Mice carrying Cnp-Cre transgene alone did not display any developmental abnormalities compared with non-Cre animals as previously reported11 and supported by our assessment of CNS angiogenesis at postnatal 10 and motor function at postnatal one month (Supplementary Fig. 3). HIF1α cKO or HIF2α cKO did not influence blood vessel density, indicating a compensatory effect of oligodendroglial HIF1α and HIF2α on angiogenesis. In contrast, HIF1α/HIF2α double cKO (refer to as HIFα cKO hereafter) significantly impaired CNS angiogenesis evidenced by reduced blood vessel density (Fig. 1a–c) and diminished EC proliferation not only in the cerebral cortex but also in the spinal cord at postnatal 14 (Fig. 1d–g), suggesting that oligodendroglial HIFα is necessary for CNS angiogenesis.
The HIFα protein is constantly translated but subjected to rapid turnover via proteasome-mediated degradation, a process in which Von Hippel-Lindau product (VHL) is essential for HIFα degradation. Therefore, we employed Cnp-Cre:Vhlfl/fl transgenic mice to genetically ablate VHL and stabilize HIFα function in oligodendroglial lineage cells (Supplementary Fig. 4). We found that the density of blood vessels and the proliferation of ECs were significantly increased in the cerebral cortex and spinal cord of Cnp-Cre:Vhlfl/fl mice compared with those of non-Cre control mice at different time points in the early postnatal CNS (Fig. 1h–j). Stabilizing HIFα in oligodendroglial lineage cells did not have a major effect on the integrity of the blood-brain (spinal cord) barrier in the adult Cnp-Cre:Vhlfl/fl mice (Supplementary Fig. 5).
Previous studies have reported that Cnp-Cre primarily targets oligodendroglial lineage cells and also a subpopulation of early neural progenitor cells12,13. To corroborate the conclusion derived from Cnp-Cre transgenic mice, we assessed CNS angiogenesis in a different animal strain Sox10-Cre:Vhlfl/fl in which Sox10-Cre mediated HIFα stabilization in the earlier stages of oligodendrocyte development in the CNS. Consistently, CNS angiogenesis was significantly increased in Sox10-Cre:Vhlfl/fl mutants, as assessed by elevated blood vessel density (Fig. 1k), EC-specific Pecam1 mRNA expression (Fig. 1l), and EC densities (Fig. 1m). Taken together, our loss (gain)-of-function results suggest that oligodendroglial HIFα is necessary and sufficient for angiogenesis and that the angiogenic regulation by oligodendroglial HIFα is independent of CNS regions.
Oligodendroglial HIFα does not regulate Wnt signaling
To determine whether HIFα in oligodendroglial lineage cells regulates Wnt/β-catenin signaling, we quantified the Wnt/β-catenin target gene Axin2, Naked1, and Notum, which are reliable readouts for the signaling activation10. We found no significant changes in the mRNA levels of those genes in HIFα-stabilized spinal cord and forebrain of Cnp-Cre:Vhlfl/fl mutants at different time points (Fig. 2a) compared with those of non-Cre controls. Consistently, western blot assay showed that the active form of β-catenin (dephosphorylated on Ser37 or Thr41) and Axin2 did not change (Fig. 2b), indicating that stabilizing oligodendroglial HIFα does not perturb the activity of Wnt/β-catenin signaling in the CNS. Furthermore, we found no significant change in the mRNA level of Wnt7a in the CNS of Cnp-Cre:Vhlfl/fl mice compared with non-Cre controls (Fig. 2c). We crossed Wnt reporter transgenic mice BAT-lacZ14 with Cnp-Cre:Vhlfl/fl mutants and found no difference in lacZ mRNA level in the spinal cord of BAT-lacZ/Cnp-Cre:Vhlfl/fl mice compared with age-matched BAT-lacZ mice (Fig. 2d).
We further assessed the activity of Wnt/β-catenin signaling in a different animal strain of Sox10-Cre:Vhlfl/fl mice. Consistent with Cnp-Cre:Vhlfl/fl mice, HIFα was stabilized in the CNS of Sox10-Cre:Vhlfl/fl mutants, as shown by the elevated expression of HIFα target gene Hk2 (Fig. 2e). However, Wnt/β-catenin signaling was not perturbed, as evidenced by similar activity of Wnt/β-catenin signaling assessed at the mRNA (Fig. 2f) and protein (Supplementary Fig. 6) levels. The unperturbed activity of Wnt/β-catenin signaling was further corroborated by evidence from a time-conditional Pdgfrα-CreERT2:Vhlfl/fl strain in which Pdgfrα-CreERT2 elicited a greater than 85% of recombination efficiency and specificity in early postnatal oligodendrocyte progenitor cells (OPCs) (Supplementary Fig. 7). Tamoxifen-induced VHL ablation in OPCs resulted in HIFα stabilization and elevated angiogenesis, as demonstrated by significant increase in the expression of HIFα target gene Hk2 and EC-specific Pecam1 (Fig. 2g) and the density of cerebral blood vessels (Fig. 2h). However, the mRNA expression of Wnt target genes Ainx2 and Sp5 (Fig. 2i) and the protein levels of active β-catenin and Naked1 (Supplementary Fig. 8) were indistinguishable between Pdgfrα-CreERT2:Vhlfl/fl mutants and non-Cre controls, indicating that Wnt/β-catenin signaling activity was not altered by oligodendroglial HIFα stabilization.
Previous study reported an autocrine activation of Wnt/β-catenin signaling in OPCs by HIFα stabilization9. To assess the autocrine activity of Wnt/β-catenin signaling, we treated purified primary OPCs with HIFα stabilizer DMOG9 in the presence or absence of HIFα signaling blocker Chetomin15 (Supplementary Fig. 9a). Our results showed that pharmacological stabilizing HIFα activated HIFα signaling target genes (Supplementary Fig. 9b) but did not activate Wnt/β-catenin target genes nor Wnt7a and Wnt7b (Supplementary Fig. 9c) in primary OPCs isolated from neonatal brain. We also quantified the activity of Wnt/β-catenin signaling in primary OPCs which were isolated from neonatal Sox10-Cre:Vhlfl/fl brain. Consistent with the in vivo data (Fig. 2e), HIFα target genes were significantly increased in primary VHL-deficient OPCs (Fig. 2j). However, neither Wnt/β-catenin target genes Axin2 and Naked1 nor Wnt7a were increased in primary VHL-deficient OPCs (Fig. 2k), suggesting that stabilizing oligodendroglial HIFα does not perturb Wnt/β-catenin signaling in primary OPCs.
To determine whether HIFα deletion affects Wnt/β-catenin signaling, we analyzed Wnt/β-catenin activity in the early postnatal CNS of Cnp-Cre:HIFα cKO and Pdgfrα-CreERT2:HIFα cKO mutants. Consistent with HIFα-stabilized mutants (Fig. 2), we found no evidence of Wnt/β-catenin signaling perturbation in both strains of HIFα cKO mutants (Supplementary Fig. 10). Collectively, our in vivo and in vitro data demonstrate that Wnt/β-catenin signaling is unlikely a downstream target of oligodendroglial HIFα as previously reported9 and suggest that oligodendroglial HIFα may regulate CNS angiogenesis independent of Wnt/β-catenin signaling.
OPC autocrine Wnt signaling is dispensable for angiogenesis
WLS is an essential factor of Wnt secretion from Wnt-producing cells and its deficiency blocks Wnt ligands from activating the downstream pathways in Wnt-receiving cells16–19. To determine whether WLS deficiency affects Wnt secretion from oligodendroglial lineage cells, we knocked down WLS in primary Wnt7a-expressing OPCs and assessed Wnt secretion and autocrine Wnt/β-catenin activity (Fig. 3a, b). Because Wnt7a has been shown as one of the major Wnt ligand genes expressed in OPCs at the mRNA level9,20, we overexpressed Wnt7a in primary OPCs. Our enzyme-linked immunosorbent assay (ELISA) of the culture medium showed that WLS knockdown significantly reduced Wnt7a concentration secreted from Wnt7a-expressing OPCs (Fig. 3c). Autocrine Wnt/β-catenin signaling was activated in Wnt7a-expressing OPCs, as evidenced by the increased expression of Wnt target genes Axin2 and Sp5 (Fig. 3d), but this activation was blocked in WLS-deficient OPCs (Fig. 3d). Our data suggest that WLS is required for Wnt secretion from OPCs.
To define the putative in vivo role of Wnt signaling in HIFα-regulated CNS angiogenesis, we generated VHL/WLS double mutant hybrids to block Wnt secretion from HIFα-stabilized oligodendroglial lineage cells (Fig. 4a). Because constitutive Sox10-Cre:Vhlfl/fl pups died at very early postnatal ages, we used an inducible Cre line Sox10-CreERT2 to stabilize HIFα and disrupt WLS (Fig. 4b, c) in Sox10+ oligodendroglial lineage cells (OPCs and differentiated oligodendroglia). Our fate-mapping data showed that Sox10-CreERT2 elicited ~60% of recombination efficiency and greater than 90% of oligodendroglial specificity in Sox10+ oligodendroglial lineage cells in the early postnatal CNS (Supplementary Fig. 11). We confirmed that HIFα’s function was indeed stabilized in the spinal cord of Sox10-CreERT2:Vhlfl/fl (HIFα-stabilized mice) and Sox10-CreERT2:Vhlfl/fl:Wlsfl/fl(HIFα-stabilized/WLS-disrupted mice), as evidenced by the elevated expression of HIFα target gene Hk2 (Fig. 4d) and Ldha (Fig. 4e) in comparison with non-Cre controls. Our analysis demonstrated that blocking Wnt secretion by disrupting WLS did not alter HIFα stabilization-elicited CNS angiogenesis in HIFα-stabilized/WLS-disrupted mice compared with HIFα-stabilized mice, which was supported by unchanged levels of endothelial Pecam1 mRNA expression (Fig. 4f) and unchanged densities of blood vessels (Fig. 4g–j), ERG+ ECs (Fig. 4k), and ERG+EdU+ dividing ECs (Fig. 4l) in the spinal cord and cerebral cortex of HIFα-stabilized/WLS-disrupted mice compared with those of HIFα-stabilized mice. These data suggest that oligodendroglial lineage-derived Wnt signaling plays a minor role in HIFα-regulated angiogenesis in the early postnatal CNS.
Next, we used a different Cre transgenic line Pdgfrα-CreERT2 to stabilize HIFα specifically in OPCs. OPC-specific HIFα stabilization enhanced blood vessel density (Fig. 5a–d) and increased the number of ERG+ ECs (Fig. 5e, f) in the spinal cord and cerebral cortex of Pdgfrα-CreERT2:Vhlfl/fl animals compared with those in non-Cre controls. However, blocking Wnt secretion from OPCs by disrupting WLS did not affect blood vessel formation and endothelial cell density in the CNS of HIFα stabilized/WLS-disrupted mice compared with HIFα stabilized mice (Pdgfrα-CreERT2:Vhlfl/fl:Wlsfl/fl versus Pdgfrα-CreERT2:Vhlfl/fl) (Fig. 5c–f). The data from two independent Cre transgenic lines collectively suggest that oligodendroglia-derived Wnt signaling is dispensable for HIFα-regulated CNS angiogenesis in vivo.
Oligodendroglial HIFα activates VEGFA
A previous study reported that VEGFA was unperturbed by oligodendroglial HIFα stabilization9. We revisited the potential connection between HIFα and VEGFA in oligodendrocytes both in vivo and in vitro. HIF1α cKO (or HIF2α cKO) alone did not alter Vegfa mRNA level in the CNS of Cnp-Cre:Hif1αfl/fl (or Cnp-Cre:Hif2αfl/fl) mutants compared with non-Cre controls (data not shown), indicating a redundancy of oligodendroglial HIF1α and HIF2α in regulating VEGFA. HIFα double cKO (i.e., Cnp-Cre:Hif1αfl/fl:Hif2αfl/fl) decreased Vegfa mRNA expression in the spinal cord (Fig. 6a) and reduced the secretion of VEGFA from primary brain OPCs into the culture medium (Fig. 6b). Conversely, genetic HIFα stabilization by VHL deletion increased Vegfa mRNA expression in the spinal cord of Cnp-Cre:Vhlfl/fl animals (Fig. 6c, d1–d4). Double fluorescent in situ hybridization confirmed that Vegfa mRNA was upregulated in Plp mRNA+ oligodendroglial lineage cells in vivo (Fig. 6e1–e2). Moreover, time-conditional and stage-specific VHL cKO demonstrated that genetic HIFα stabilization activated VEGFA not only in PDGFRα+ OPCs (Pdgfrα-CreERT2:Vhlfl/fl strain) (Fig. 6f) but also in PLP+ oligodendroglia (Plp-CreERT2:Vhlfl/fl strain) (Fig. 6g). Pharmacological DMOG treatment increased Vegfa mRNA expression and HIFα signaling blocker Chetomin prevented DMOG-induced Vegfa activation in primary OPCs purified from neonatal murine brains (Fig. 6h). Furthermore, Vegfa mRNA was elevated by greater than 3-fold in primary OPCs purified from neonatal Sox10-Cre:Vhlfl/fl mice compared with those from non-Cre littermate controls (Fig. 6i). All these data suggest that VEGFA is regulated by HIFα in oligodendroglial lineage cells.
Oligodendroglial HIFα regulates angiogenesis through VEGFA
The regulation of VEGFA by oligodendroglial HIFα led us to hypothesize that VEGFA may be a crucial downstream molecule that couples oligodendroglial HIFα and CNS endothelial cell proliferation and vessel formation. To test this hypothesis, we generated Pdgfrα-CreERT2:Vhlfl/fl:Vegfafl/fl (HIFα-stabilized/VEGFA-disrupted), Pdgfrα-CreERT2:Vhlfl/fl (HIFα-stabilized), and non-Cre control mice (Fig. 7a, b). The mRNA level of EC-specific marker PECAM1 was significantly attenuated in the spinal cord of PdgfrαCreERT2:Vhlfl/fl: Vegfafl/fl mice compared with that of Pdgfrα-CreERT2:Vhlfl/fl mice (Fig. 7c). The densities of blood vessels (Fig. 7d, e), ERG+ total ECs (Fig. 7f), and ERG+BrdU+ proliferating ECs (Fig. 7g) were all significantly reduced in the spinal cord and cerebral cortex of Pdgfrα-CreERT2:Vhlfl/fl:Vegfafl/fl mice compared with those of Pdgfrα-CreERT2:Vhlfl/fl mice. These data demonstrate that VEGFA disruption attenuates oligodendroglial HIFα-regulated CNS angiogenesis, thus providing unambiguous in vivo data arguing for an essential role of VEGFA in coupling oligodendroglial HIFα function and CNS angiogenesis.
Astroglial HIFα regulates CNS angiogenesis via Wnt signaling
Astroglial maturation is also temporally and functionally coupled with postnatal CNS angiogenesis. We assess the connection of astroglial HIFα and Wnt/β-catenin activation in the CNS. We first used the mouse Gfap promoter-driven constitutive Cre, i.e. mGfap-Cre to genetically stabilize HIFα in astroglia. The efficiency of mGfap-Cre-mediated recombination among astroglial lineage cells, quantified by Cre-mediated EYFP reporter, was low (~35%) in the CNS in the early postnatal CNS by P10 (Supplementary Fig. 12a–c) and progressively increased during postnatal CNS development (Supplementary Fig. 12d–f). Our fate-mapping data showed that EYFP reporter, which is an indicator of mGfap-Cre activity, was expressed in GFAP+ or S100β+ astrocytes, but not in Sox10+ oligodendroglial lineage cells, NeuN+ neurons (Fig. 8a), or ERG+ ECs (data not shown) in the spinal cord and the cerebral cortex of adult mGfap-Cre:Rosa26-EYFP mice at P60, confirming that mGfap-Cre primarily targets astroglial lineage cells in those CNS regions.
We observed a significant increase in the density of Laminin+ blood vessels (Fig. 8b, c) and in the mRNA expression of EC-specific PECAM1 (Fig. 8d) throughout the CNS of mGfap-Cre:Vhlfl/fl mutants compared with non-Cre control mice by P30 when Cre-mediated recombination efficiency was greater than 80% (Fig. 8a, Supplementary Fig. 12). Double immunohistochemistry showed that blood-borne macromolecule IgG was confined to Laminin+ blood vessels in mGfap-Cre:Vhlfl/fl mice, a similar pattern to that in age-matched non-Cre controls (Fig. 8e, arrowheads), indicating that the function of the blood-brain (spinal cord) barrier does not appear compromised although the vessel density is elevated.
Unexpectedly, we found that stabilizing HIFα in astroglial lineage cells (Fig. 8f) remarkably activated Wnt/β-catenin signaling in the CNS of mGfap-Cre:Vhlfl/fl mice, as shown by significant elevation in the expression of Wnt/β-catenin signaling target genes Axin2 and Notum in spinal cord and brain (Fig. 8g). Histological (Fig. 8h) and Western blot (cf Fig. 9a, b) assay demonstrated that the active form of β-catenin (dephosphorylated on Ser37 or Thr41) was significantly increased in mGfap-Cre:Vhlfl/fl mice. Double immunohistochemistry confirmed the presence of elevated active β-catenin in PECAM1+ ECs (Fig. 8i, arrowheads). Collectively, our data suggest that stabilizing HIFα in astroglial lineage cells increases CNS angiogenesis and activates Wnt/β-catenin signaling in ECs.
Wnt/β-catenin signaling activation in ECs by astroglial HIFα stabilization led us to hypothesize that astroglia-derived Wnt signaling may instead play a major role in HIFα-regulated CNS angiogenesis. To test this hypothesis, we generated mGfap-Cre:Vhlfl/fl:Wlsfl/fl mice to stabilize HIFα’s function and simultaneously disrupting Wnt secretion from HIFα-stabilized astroglia. Our data showed that Wnt signaling activity was significantly reduced in the spinal cord of mGfap-Cre:Vhlfl/fl:Wlsfl/fl mice compared with that of mGfap-Cre:Vhlfl/fl mice (Fig. 9a, b), thus verifying the efficacy of blocking astroglia-derived Wnt signaling in vivo by WLS deletion. Intriguingly, disrupting astroglia-derived Wnt signaling significantly reduced the densities of blood vessels (Fig. 9c–e) and ERG+ ECs (Fig. 9f–h) in the CNS of mGfap-Cre:Vhlfl/fl:Wlsfl/fl double mutant mice compared with mGfap-Cre:Vhlfl/fl mice, indicating that astroglia-derived Wnt signaling is a downstream mediator of astroglial HIFα-regulated CNS angiogenesis.
Our results indicated that the constitutive mGfap-Cre elicited a poor recombination efficiency in early postnatal astrocytes (Supplementary Fig. 12). To determine whether early postnatal astrocytes regulate CNS angiogenesis through HIFα-activated Wnt signaling, we generated Aldh1l1-CreERT2:Vhlfl/fl:Wlsfl/fl mutants. Our data demonstrated a greater than 90% of recombination efficiency and 95% of astroglial specificity in the spinal cord and cerebral cortex of Aldh1l1-CreERT2:Rosa26-EYFP at P8 when tamoxifen was injected at P1, P2 and P3 (Supplementary Fig. 13). Consistent with the data derived from mGfap-Cre:Vhlfl/fl:Wlsfl/fl strain, we found that the densities of blood vessels and ECs were significantly increased in Aldh1l1-CreERT2:Vhlfl/fl mutants compared with those in non-Cre controls and that simultaneous WLS ablation significantly reduced the densities of blood vessels and ECs in the cortex and spinal cord of Aldh1l1-CreERT2:Vhlfl/fl:Wlsfl/fl mutants compared with those of Aldh1l1-CreERT2:Vhlfl/fl animals at early postnatal age of P8 (Fig. 10). These data provide a strong genetic proof that HIFα-activated Wnt signaling is a major downstream pathway by which astroglia regulate angiogenesis during postnatal CNS development.
Discussion
The maturation of glial cells including oligodendroglia and astroglia in the developing human and murine brain is temporally and functionally coupled with the maturation of the CNS vascular network21. The regulation of CNS angiogenesis by glial cells is critical for postnatal CNS development and investigating the molecular underpinnings of CNS angiogenesis has clinical implications in neural repair after CNS damage in which hypoxia is commonly present4,21,22. In this study, we employed a battery of genetic mutant mice and presented several significant findings: (1) oligodendroglial HIFα is necessary and sufficient for postnatal CNS angiogenesis and this regulation occurs in a manner independent of CNS regions; (2) in sharp contrast to the previous report9, HIFα stabilization in oligodendroglial lineage cells does not perturb Wnt/β-catenin signaling, but remarkably activates VEGF, and genetically blocking oligodendroglia-derived VEGF but not Wnt reduces oligodendroglial HIFα-regulated CNS angiogenesis; (3) Wnt signaling is a downstream pathway by which astroglial HIFα regulates CNS angiogenesis. Our findings represent an alternative view in our mechanistic understanding of oligodendroglial HIFα-regulated angiogenesis from a Wnt-dependent/VEGF-independent view9 to a VEGF-dependent/Wnt-independent one, and also unveil a glial cell type-dependent HIFα-Wnt axis (oligodendroglial vs astroglia) in regulating CNS angiogenesis (Supplementary Fig. 14).
Previous data suggested that the regulation of Wnt/β-catenin signaling (activation or repression) by HIFα is cell type and/or context-dependent10,23–27. It is important to determine whether HIFα in CNS glial cells differentially regulates Wnt/β-catenin signaling in vivo. A recent study reported that oligodendroglial HIFα could activate Wnt/β-catenin signaling not only in oligodendroglial lineage cells but also in endothelial cells through HIFα-mediated Wnt7a/7b expression9. However, the in vivo and in vitro data presented in this study do not support this assertion. Here, we employed five different strains of oligodendroglial Cre (two constitutive Cre and three inducible Cre) to genetically stabilize HIFα and found no evidence of Wnt/β-catenin activation or Wnt7a/7b upregulation in the brain and the spinal cord and in primary OPCs. The failure to detect Wnt/β-catenin activation is unlikely due to the inefficiency of HIFα stabilization because the canonical HIFα target genes, for example, those which are involved in glycolysis, are consistently and significantly upregulated in our transgenic animals and in primary OPCs, thus verifying the efficacy of HIFα stabilization. In sharp contrast, we found that Wnt/β-catenin signaling activity is significantly upregulated in the CNS of astroglial HIFα-stabilized mice, suggesting that our experimental approach is effective in quantifying the changes of Wnt/β-catenin activity and that the regulation of Wnt/β-catenin signaling by HIFα is glial cell type-dependent in the CNS.
Inspired by glial cell type (oligodendroglia vs astroglia)-dependent activation of Wnt/β-catenin signaling, we proposed a working model in which HIFα-activated Wnt signaling regulates endothelial cell proliferation and vessel formation in a cell type-dependent manner (Supplementary Fig. 14). To avoid the intrinsic caveats of pharmacological compounds and in vitro culture systems, we employed in vivo genetic models of VHL/WLS double cKO to stabilize HIFα and simultaneously disrupt the secretion of Wnt ligands. Indeed, our data demonstrate that WLS-deficiency decreases Wnt secretion and Wnt7a-induced autocrine Wnt/β-catenin signaling in primary OPCs and that disrupting WLS in astroglia reduces the activity of astroglial HIFα-regulated Wnt/β-catenin signaling in the CNS. Based on VHL/WLS double cKO systems, we provide strong genetic evidence that HIFα-regulated Wnt signaling from astroglia but not oligodendroglia plays a crucial role in regulating postnatal CNS angiogenesis. Our findings argue against a major role oligodendroglia-derived/HIFα-activated Wnt/β-catenin signaling in angiogenesis in the developing murine CNS as previously reported9.
There are 19 Wnt ligands in rodents, which can be grossly classified into canonical and non-canonical sub-types depending on the necessity of β-catenin for the signaling activation10. WLS ablation blocks the secretion of all Wnt members from Wnt-producing cells16–19,28. In our genetic models, we demonstrate that ablation of WLS remarkably reduces astroglial HIFα-mediated canonical Wnt/β-catenin signaling. However, we cannot exclude the possibility that astroglia-derived non-canonical Wnt signaling is also altered in our genetic manipulation which may be potentially involved in CNS angiogenic regulation29. Moreover, it remains unclear which Wnt ligand(s) plays a major role in coupling astroglial HIFα with CNS angiogenesis. Our preliminary data do not support a major role of Wnt7a/7b, because neither Wnt7a nor Wnt7b expression was activated in oligodendroglial and astroglial HIFα-stabilized CNS. Future studies are needed to pinpoint which Wnt ligand(s) are the downstream mediator(s) of astroglial HIFα-regulated CNS angiogenesis.
VEGF (i.e. VEGFA) is a well-established angiogenic and neurotrophic factor in the CNS4,30–35. VEGFA regulates angiogenesis in the developing and adult CNS through its membrane-bound receptors VEGFR-1(Flt1) and VEGFR-2 (Kdr)30. In the early postnatal CNS, VEGFR-1 and 2 are highly expressed in the vascular ECs. However, the ligand VEGFA is barely detectable in the vascular ECs but highly expressed in the parenchymal neural cells including oligodendroglial lineage cells20,36–38. The previous study suggested that the HIFα-VEGF connection did not occur in the CNS oligodendroglia9 although this connection was demonstrated in the retina39. In this study, we found that oligodendroglial HIFα cKO reduces VEGFA whereas oligodendroglial HIFα stabilization increases VEGFA expression, indicating that HIFα transcriptionally regulates VEGFA in oligodendroglial lineage cells. Further corroborating these findings, purified primary OPCs respond to HIFα signaling stabilizer (DMOG) and blocker (Chetomin) by activating and inactivating VEGFA, respectively. Our results are consistent with previous data showing that VEGFA is a direct transcriptional target of HIFα40–42. By leveraging our unique in vivo genetic models of VHL/VEGFA double cKO, we unequivocally prove that VEGFA is an essential downstream molecule that couples oligodendroglial HIFα function and vascular angiogenesis in the CNS, which is different from Yuen et al.9, who reported that VEGFA was unchanged in the CNS of oligodendroglial HIFα-stabilized mutants. The discrepancy may presumably reflect the intrinsic differences of in vitro pharmacological interventions and in vivo genetic manipulations.
It has been suggested that Wnt signaling regulates VEGF, or vice versa, to control angiogenesis43–45. It is possible that Wnt/β-catenin signaling is required for, or synergistically regulates, HIFα-activated VEGFA expression. Our data do not support this possibility. First, stabilizing oligodendroglial HIFα activates VEGFA but not Wnt/β-catenin signaling. Second, VEGF expression is indistinguishable in the CNS of oligodendroglial VHL/WLS double cKO mutants from that of oligodendroglial VHL single cKO mutants (data not shown), indicating that oligodendroglial-derived Wnt signaling plays a minor role in VEGFA expression. Third, Wnt/β-catenin activity is comparable in the CNS of oligodendroglial VHL/VEGFA double cKO mutants and VHL single cKO mutants, implying that oligodendroglia-derived VEGFA has no regulatory role in Wnt/β-catenin activity. Together, our results do not support a major interplay between oligodendroglial HIFα-activated VEGFA and Wnt/β-catenin signaling in modulating CNS angiogenesis.
Previous studies including those from our own laboratory10,12,46–49 have shown that dysregulated Wnt/β-catenin activity invariably inhibits oligodendrocyte differentiation and myelination. Given the normal level of Wnt/β-catenin activity in the CNS of oligodendroglial HIFα-stabilized mutants, our study will spark renewed interests in studying Wnt-independent mechanisms underlying the impairment of oligodendroglial differentiation and myelination in HIFα-stabilized mutants as previously reported9. Interestingly, HIFα is stabilized and enriched in oligodendroglia in the active demyelinating lesions and normal-appearing white matter (NAWM) of multiple sclerosis patient brains50–53. We show that HIFα stabilization in oligodendrocytes remarkably activates the angiogenic and neurotrophic factor VEGF in the CNS. The genetic models generated in our study also provide a powerful tool in determining the role of HIFα stabilization in OPCs and oligodendrocytes in the pathophysiology of demyelination and remyelination in multiple sclerosis and other neurological disorders in which hypoxia-like tissue injury occurs.
Methods
Animals
A total of 14 transgenic strains were used in this study. Cnp-Cre mice (RRID: MGI_3051754)11, Sox10-Cre (RRID: IMSR_JAX:025807), Sox10-CreERT2 (RRID:IMSR_JAX: 027651), Pdgfrα-CreERT2 (RRID: IMSR_JAX:018280), Aldh1l1-CreERT2 (RRID: IMSR_JAX:029655), Plp-CreERT2 (RRID: IMSR_JAX:005975), mGfap-Cre (RRID: IMSR_JAX:024098), Hif1α-floxed (RRID: IMSR_JAX:007561), Hif2α-floxed (RRID: IMSR_JAX:008407), Vhl-floxed (RRID: IMSR_JAX:012933), Wls-floxed (RRID: IMSR_JAX:012888), Vegfa-floxed (MGI:1931048)54, Bat-lacZ (RRID: IMSR_JAX:005317), Rosa26-EYFP (RRID: IMSR_JAX:006148). Animals were housed at 12h light/dark cycle with free access to food and drink, and both males and females were used in this study. The single transgenic mice were crossed to generate double or triple transgenic mice indicated in the study. All Cre transgene was maintained as heterozygous. All transgenic mice were maintained on a C57BL/6 background. Animal protocols were approved by Institutional Animal Care and Use Committee at the University of California, Davis.
Primers used for genotyping Hif1α-floxed, Hif2α-floxed, and Vhl-floxed and for detecting Cre-mediated DNA deletion (as in Figs. 1a and 2a, b) were derived from previous study55 and listed here. Hif1α-F1: 5′-TTGGGGATGAAAACATCTGC-3′, Hif1α-F2: 5′-GCAGTTAAGAGCACTAGTTG-3′, Hif1α-R: 5′-GGAGCTATCTCTCTAGACC-3′), Hif2α-F1:5′-CAGGCAGTATGCCTGGCTAATTCCAGTT-3′, Hif2α-F2: 5′-CTTCTTCCATCATCTGGGATCTGGGACT-3′, Hif2α-R: 5′-GCTAACACTGTACTGTCTGAAAGAGTAGC-3′, Vhl-F1: 5′-CTGGTACCCACGAAACTGTC-3′, Vhl-F2: 5′-CTAGGCACCGAGCTTAGAGGTTTGCG-3′ Vhl-R: 5′-CTGACTTCCACTGATGCTTGTCACAG-3′. Primers used for genotyping Wls-floxed for detecting Cre-mediated DNA deletion (as in Fig. 7b) were derived from previous study18 and listed here. Wls-F1: 5′-CTTCCCTGCTTCTTTAAGCGTC-3′, Wls-F2: 5′-AGGCTTCGAACGTAACTGACC-3′, Wls-R: 5′-CTCAGAACTCCCTTCTTGAAGC-3′
Tamoxifen and BrdU (or EdU) treatment
Tamoxifen (TM) (T5648, Sigma) was dissolved in mixture of ethanol and sunflower oil (1:9 by volume) at a concentration of 30 mg/ml14. Mice were administrated intraperitoneally (i.p.) with tamoxifen at dose of 200 μg/g body weight at time points indicated in each figure. BrdU (B5002, Sigma) or EdU (A10044, Thermo Fisher Scientific) was freshly dissolved in 0.9% sterile saline at a concentration of 10 mg/ml. BrdU or EdU was i.p. injected to animals at a dose of 100 μg/g body weight at time-points indicated in the figures. Tamoxifen was administered to both the controls and the inducible floxed mice in all experiments involving inducible Cre-LoxP approach.
Primary OPC culture
Primary mixed glial culture (MG) was prepared from the forebrains of neonatal pups between ages P0 and P2. The isolated cortical tissues were dissociated by papain dissociation kit (#LK003176, Worthington) supplemented with DNase I (250 U/ml; #D5025, Sigma) and D-(+)-glucose (0.36%; #0188 AMRESCO) in 33 °C/10% CO2 for 90 min. Next, the tissues were transferred in PDS Kit-Inhibitor solution (#LK003182, Worthington). Tissue chunks were triturated, and then collect the cell suspension supernatant. After centrifugation, cells were plated on poly-D-lysine (PDL, #A003-E, Millipore)-coated 10 cm dishes (#130182, Thermo Scientific) in high-glucose DMEM medium (#1196092, Thermo Fisher) with 10% heat-inactivated fetal bovine serum (#12306-C, Sigma) and penicillin/streptomycin (P/S, #15140122, Thermo Fisher). After 24 h, attached cells were washed with HBSS (#24020117, Thermo Fisher) to remove serum, and maintained with serum-free growth medium (GM), a 3:7 mixture (v/v) of B104 neuroblastoma-conditioned medium, 10 ng/ml Biotin (#B4639, Sigma), and N1 medium (high-glucose DMEM supplemented with 5 μg/ml insulin (#I6634, Sigma), 50 μg/ml apo-transferrin (#T2036, Sigma), 100 μM Putrescine (#P5780, Sigma), 30 nM Sodium selenite (#S5261, Sigma), 20 nM Progesterone (#P0130, Sigma). We performed immunopanning 96 h after GM maintenance. Before immunopanning, cells were resuspended in panning solution (0.1% BSA in N1 medium). The cells were panned once with the anti-Thy1.2 antibody (#105302, Biolegend) for negative immunopanning and then panned once with the anti-NG2 antibody (#AB5320, Millipore) for positive immunopanning. OPCs were cultured on PDL-coated plates with complete GM. The complete GM consisted of GM with 5 ng/ml FGF (#450-33, Peprotech), 4 ng/ml PDGF-AA (#315-17, Peprotech), 50 µM Forskolin (#6652995, Peprotech,) and glutamax (#35050, Thermo Fisher). To induce differentiation, the medium was switched to differentiation medium (DM), which consists of 12.5 μg/ml insulin, 100 μM Putrescine, 24 nM Sodium selenite, 10 nM Progesterone, 10 ng/ml Biotin, 50 μg/ml Transferrin (#T8158, Sigma), 30 ng/ml 3,3′,5-Triiodo-L-thyronine (#T5516, Sigma), 40 ng/ml L-Thyroxine (#T0397, Sigma-Aldrich), glutamax and P/S in F12/high-glucose DMEM, 1:1 in medium (#11330032, Thermo Fisher Scientific).
HIFα signaling stabilization and inhibition in vitro
Purified brain primary OPCs were pre-incubated with 100 nM Chetomin or DMSO control for 2 h, and then switched to the fresh culture medium with 1 mM Dimethyloxalylglycine (DMOG, D3695, Sigma) in the presence of 100 nM Chetomin (C9623, Sigma) or DMSO (D8418, Sigma) control for 7 h before RNA preparation.
VEGFA ELISA assay
Cell culture medium of primary OPCs from Non-Cre control and Cnp-Cre, Hif1αfl/fl, Hif2αfl/fl were collected for VEGF measurement. Endogenous VEGF concentrations were determined using a mouse-specific VEGF Quantikine ELISA kit (t#MMV00, R&D System) according to the manufacture’s instruction.
Transfection in primary OPCs and ELISA assay
Primary OPCs was transfected with Wls-ShRNA (TRCN 0000 234932, Mission ShRNA bacterial Glycerol stock NM_026582) and ShRNA scramble control (Mission TRC2 PlkO.5-PURO Non-Mammalian shRNA control Plasmid), Wnt7a plasmid pLCN-Wnt7a-HA (Addgene, #18036) and empty pLCN-exp (Addgene, #64865) at the time points indicated in Fig. 3a. The transfection was done by using FuGENE6 Transfection reagent (Promega, #E2691, lot#000371257). The Wnt7a in OPCs cell medium was measured by using mouse Wnt7a ELISA kit (Cusabio, #CSB-EL026141MO, Lot#G19147708) according to the manual of the kit.
Immunohistochemistry and blood vessel quantification
Study mice were perfused with ice-cold phosphate buffered saline (PBS, pH = 7.0, Catalog #BP399-20, Fisher Chemical), and then post-fix in fresh 4% paraformaldehyde (PFA, Catalog #1570-S, Electron Microscopy Science,PA) at room temperature(RT) for 2 h. The CNS tissue was washed in ice-cold PBS for three times, 15 min each time. The samples were cryoprotected with 30% sucrose in PBS (Sucrose, Catalog #S5-3, Fisher Chemical) for 20 h followed by sectioning. Sixteen microns thick sections were serially collected and stored in −80 °C. Immunohistochemistry was conducted as below: slices were air dry in RT for at least 1 h, and then were blocked with 10% Donkey (Dky) serum for 1 h at RT. Tissue was incubated with primary antibody overnight at 4 °C. Slices were washed for 15 min in PBST (PBS with 0.1% Tween-20) for three times, then incubated with fluorescence conjugated secondary antibody (1:500; Alexa-fluorescence from Jackson ImmunoResearch) for 1.5 h at RT. Slices were washed 15 min in PBST (PBS with 0.1% Tween-20) for three times. The immunostaining was done before incubating with DAPI nuclear staining for 10 min56,57. The information of primary antibodies used for immunohistochemistry in the study were listed in Supplementary Table 1. For BrdU immunostaining, sections were pretreated with fresh-made 2N HCl (#320331, Sigma) followed by the above immunostaining procedures.
To quantify blood vessel density, we used projected confocal images at 40x magnification (Nikon C1) followed by NIH ImageJ automated processing. At least three sections from each mouse were used for ImageJ quantification. Ten-micron-thick optical sections from confocal z-stack images were projected into a flattened image. The parameter setting of z-stack confocal imaging is below: total optical thickness, 10 μm, step size, 0.5 μm, total number optical slices, 21. The volume-rendered confocal images were subsequently imported to NIH ImageJ 1.46r for quantifying Laminin-positive blood vessel density using a customer-defined Macro program. The total area and Laminin-occupying area were derived and from ImageJ and exported to Microsoft Excel for calculating the percent of Laminin-occupying area among assessed total CNS area.
mRNA In Situ hybridization (ISH)
We employed the PCR and in vitro transcription to prepare cRNA probes targeting Vegfa and Plp58. Targeted sequences of Vegfa and Plp were generated by PCR. The primers used were: Vegfa-Forward: GGATATGTTTGACTGCTGTGGA; Vegfa-Reverse: AGGGAAGATGAGGAAGGGTAAG; Plp-Forward: GGGGATGCCTGAGAAGGT; Plp-Reverse: TGTGATGCTTTCTGCCCA. We added the T7 (GCGTAATACGACTCACTATAGGG) and SP6 (GCGATTTAGGTGACACTATAG) promoter sequences to the 5’ of the forward and reverse primers, respective. The SP6 and T7 promoter sequences are recognized by the SP6 and T7 RNA polymerase, respectively, in the subsequence in vitro transcription. PCR products of Vegfa and Plp amplification were used as DNA templates to transcribe into Vegfa and Plp cRNA probes in vitro using SP6 RNA polymerase. T7 RNA polymerase-mediated transcription of RNA was used as negative control. DIG-UTP or FITC-UTP was used to generate DIG- or FITC-labeled cRNA probes.
Single or dual mRNA ISH was done using our previous protocols58. Frozen sections of 14 μm thickness were used. The concentration of cRNA probe we used was 100 ng/100 μl hybridization buffer. Hybridization was conducted at 65 °C for 18–20 h. After hybridization, sections were treated with 10 μg/ml RNase A to eliminate nonspecific cRNA binding. For single mRNA ISH with DIG-labeled cRNA probes, DIG was recognized by alkaline phosphatase (AP)-conjugated anti-DIG (#11093274910, Sigma) antibody and DIG signals were visualized by the NBT/BCIP (#72091, Sigma) method. For dual fluorescence mRNA ISH (Vegfa and Plp), FITC-labeled Plp cRNA probe and DIG-labeled Vegfa cRNA probe were applied to frozen sections simultaneously during the hybridization step. The FITC signals were visualized by tyramide signal amplification (TSA) fluorescence system (#NEL747A, Perkin Elmer) according to the manufacturer’s instructions using horseradish peroxidase (HRP)-IgG Fraction Monoclonal Mouse Anti-Fluorescein (#200-032-037, Jackson ImmunoResearch). DIG signals were visualized by a HNPP fluorescent kit (#11758888001, Sigma) according to the manufacturer’s instructions using AP-conjugated anti-DIG Fab2 antibody (#11093274910, Sigma).
Western blot
Protein concentration was assessed by BCA protein assay kit (#23225, Thermo Fisher Scientific). Twenty microgram protein lysates were separated on AnykD Mini-PROTEAN TGX precast gels (#4569035, BIO-RAD) or 10% Mini-PROTEAN TGX precast gels (#4561035, BIO-RAD). The proteins were transferred onto 0.2 μm nitrocellulose membrane (#1704158, BIO-RAD) by Trans-blot Turbo Transfer system (#1704150, BIO-RAD). The membranes were blocked with 5% BSA (#9998, Cell signaling) for 1h at room temperature and were incubated overnight with primary antibodies (Supplementary Table 2) at 4 °C. The membranes were washed 3 times with 10 mm Tris-HCl (pH 7.5) containing 150 mM NaCl and 0.1% Tween-20 (TBST) and were incubated with horseradish peroxidase-conjugated goat anti-rabbit (31460, RRID: AB_228341, Thermo Fisher Scientific) or anti-mouse (31430, RRID: AB_228307, Thermo Fisher Scientific) for 1h at room temperature. After incubation, the membranes were washed three times with TBST. Specific binding was detected using Western Lightening Plus ECL (NEL103001EA, Perkin Elmer). NIH Image J 1.44p was used to quantify protein expression levels by analyzing the scanned grey-scale films.
RNA preparation and RT-qPCR
Total RNA was extracted by using Qiagen RNeasy for lipid tissues (74804, Qiagen) with additional on-column DNase I digestion to remove genomic DNA contamination. The quality and quantity of RNAs were analyzed by the Nanodrop oneC microvolume UV-Vis Spectrophotometer (ND-ONEC-W, Thermo Fisher Scientific). cDNA was synthesized by Qiagen Omniscript RT Kit (205111, Qiagen). The relative mRNA level of indicated genes was normalized to that of the internal control Hsp90 and calculated by the equation 2^(Ct(cycle threshold) of Hsp90 − Ct of indicated genes). The gene expression levels in control groups were normalized to 1. RT-qPCR was conducted by QuantiTect SYBR® Green PCR Kit (204145, QIAGEN) approaches on Agilent MP3005P thermocycler. The qPCR primers used in the study were listed in Supplementary Table 3.
Statistical analyses
Quantification was performed by blinded observers. All measurements were taken from distinct mice and quantitative data are presented as means ± standard deviation (s.d.). We used scatter dot plots to present the quantification data throughout our manuscript. Each dot (circle, square, or triangle) in the scatter dot plots represents one mouse or one independent experiment. Shapiro–Wilk approach was used for testing data normality. F test was used to compare the equality of variances of two groups whereas Browne–Forsythe test was used for comparing the equality of variances of three or more groups. The statistical methods were described in the figure legends and P value was presented in each graph. For unpaired, two-tailed Student’s t test, t value and degree of freedom (df) were presented as t(df) in figure legends. Welch’s correction was used for Student’s t test if the variances of two groups were unequal after Browne–Forsythe test. For comparisons among three or more groups with equal variances (tested by Browne–Forsythe approach), ordinary one-way ANOVA was used followed by Tukey’s multiple comparisons, otherwise Welch’s ANOVA was used followed by unpaired t test with Welch’s correction. In ordinary ANOVA, the F ratio and DFn and DFd was presented as F(DFn,DFd) in the figure legends where DFn stands for degree of freedom numerator and DFd for degree of freedom of denominator. In Welch’s ANOVA, the Welch’s F ratio, W and DFn and DFd was presented as W(DFn,DFd) in the figure legends. All data plotting and statistical analyses were performed using GraphPad Prism version 8.0. P value less than 0.05 was considered as significant, whereas greater than 0.05 was assigned as not significant (ns).
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Supplementary information
Acknowledgements
This study was supported by the grants funded by NIH/NINDS (R21NS109790, R01NS094559, and R21NS093559 to F.G.) and Shriners Hospitals for Children (86100, 85200-NCA16, 85107-NCA-19 to F.G., 84307-NCAL to S.Z.).
Source Data
Author contributions
F.G. conceived the original idea, led the project, and wrote the paper. S.Z. and B.K. conceived the idea, designed and performed experiments, analyzed data, and wrote the paper. X.Z., X.G., Y.W., Z.L., P.P., K.F., and A.W. analyzed data and edit the paper. All the authors provided feedback and comments on the paper.
Data availability
The source data underlying Figs. 1b, c, e–m, 2a–k, 3b–d, 4c–f, h, j, k, l, 5c–f, 6a–c, f–i, 7a–g, 8c, d, f–g, 9a, b, d, e, g, h, 10b, d, Supplementary Figs. 3b–d, 4c, f, g, 6, 7b, 8a, b, 9b, c, 10a–d, 11b, 12b, c, e, f, 13b are provided as a Source Data file. The data that support this study are available from the corresponding author upon reasonable request.
Competing interests
The authors declare no competing interests.
Footnotes
Peer review information Nature Communications thanks Robert Miller, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors contributed equally: Sheng Zhang, Bokyung Kim.
Supplementary information
Supplementary information is available for this paper at 10.1038/s41467-020-15656-4.
References
- 1.Harb R, Whiteus C, Freitas C, Grutzendler J. In vivo imaging of cerebral microvascular plasticity from birth to death. J. Cereb. Blood Flow. Metab. 2013;33:146–156. doi: 10.1038/jcbfm.2012.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Paredes I, Himmels P, Ruiz de Almodovar C. Neurovascular communication during CNS development. Dev. Cell. 2018;45:10–32. doi: 10.1016/j.devcel.2018.01.023. [DOI] [PubMed] [Google Scholar]
- 3.Xiong Y, Mahmood A, Chopp M. Angiogenesis, neurogenesis and brain recovery of function following injury. Curr. Opin. Investig. Drugs. 2010;11:298–308. [PMC free article] [PubMed] [Google Scholar]
- 4.Vallon M, Chang J, Zhang H, Kuo CJ. Developmental and pathological angiogenesis in the central nervous system. Cell Mol. Life Sci. 2014;71:3489–3506. doi: 10.1007/s00018-014-1625-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ivanovic Z. Hypoxia or in situ normoxia: the stem cell paradigm. J. Cell Physiol. 2009;219:271–275. doi: 10.1002/jcp.21690. [DOI] [PubMed] [Google Scholar]
- 6.Dengler VL, Galbraith M, Espinosa JM. Transcriptional regulation by hypoxia inducible factors. Crit. Rev. Biochem Mol. Biol. 2014;49:1–15. doi: 10.3109/10409238.2013.838205. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148:399–408. doi: 10.1016/j.cell.2012.01.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Tomita S, et al. Defective brain development in mice lacking the Hif-1alpha gene in neural cells. Mol. Cell Biol. 2003;23:6739–6749. doi: 10.1128/MCB.23.19.6739-6749.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Yuen TJ, et al. Oligodendrocyte-Encoded HIF Function Couples Postnatal Myelination and White Matter Angiogenesis. Cell. 2014;158:383–396. doi: 10.1016/j.cell.2014.04.052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Guo, F. et al. Canonical Wnt signaling in the oligodendroglial lineage-puzzles remain. Glia, 10.1002/glia.22813 (2015). [DOI] [PubMed]
- 11.Lappe-Siefke C, et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat. Genet. 2003;33:366–374. doi: 10.1038/ng1095. [DOI] [PubMed] [Google Scholar]
- 12.Lang J, et al. Adenomatous polyposis coli regulates oligodendroglial development. J. Neurosci. 2013;33:3113–3130. doi: 10.1523/JNEUROSCI.3467-12.2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Tognatta R, et al. Transient Cnp expression by early progenitors causes Cre-Lox-based reporter lines to map profoundly different fates. Glia. 2017;65:342–359. doi: 10.1002/glia.23095. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Hammond E, et al. The Wnt effector transcription factor 7-like 2 positively regulates oligodendrocyte differentiation in a manner independent of Wnt/beta-catenin signaling. J. Neurosci. 2015;35:5007–5022. doi: 10.1523/JNEUROSCI.4787-14.2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Viziteu E, et al. Chetomin, targeting HIF-1 alpha/p300 complex, exhibits antitumour activity in multiple myeloma. Br. J. Cancer. 2016;114:519–523. doi: 10.1038/bjc.2016.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Banziger C, et al. Wntless, a conserved membrane protein dedicated to the secretion of Wnt proteins from signaling cells. Cell. 2006;125:509–522. doi: 10.1016/j.cell.2006.02.049. [DOI] [PubMed] [Google Scholar]
- 17.Bartscherer K, Pelte N, Ingelfinger D, Boutros M. Secretion of Wnt ligands requires Evi, a conserved transmembrane protein. Cell. 2006;125:523–533. doi: 10.1016/j.cell.2006.04.009. [DOI] [PubMed] [Google Scholar]
- 18.Carpenter AC, Rao S, Wells JM, Campbell K, Lang RA. Generation of mice with a conditional null allele for Wntless. Genesis. 2010;48:554–558. doi: 10.1002/dvg.20651. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Carpenter AC, et al. Wnt ligands from the embryonic surface ectoderm regulate ‘bimetallic strip’ optic cup morphogenesis in mouse. Development. 2015;142:972–982. doi: 10.1242/dev.120022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 2014;34:11929–11947. doi: 10.1523/JNEUROSCI.1860-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Reemst K, Noctor SC, Lucassen PJ, Hol EM. The indispensable roles of microglia and astrocytes during brain development. Front Hum. Neurosci. 2016;10:566. doi: 10.3389/fnhum.2016.00566. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ma S, Huang Z. Neural regulation of CNS angiogenesis during development. Front Biol. (Beijing) 2015;10:61–73. doi: 10.1007/s11515-014-1331-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Chen D, et al. HIF-1alpha inhibits Wnt signaling pathway by activating Sost expression in osteoblasts. PLoS ONE. 2013;8:e65940. doi: 10.1371/journal.pone.0065940. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Mazumdar J, et al. O2 regulates stem cells through Wnt/beta-catenin signalling. Nat. Cell Biol. 2010;12:1007–1013. doi: 10.1038/ncb2102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Kaidi A, Williams AC, Paraskeva C. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat. Cell Biol. 2007;9:210–217. doi: 10.1038/ncb1534. [DOI] [PubMed] [Google Scholar]
- 26.Majmundar AJ, et al. HIF modulation of Wnt signaling regulates skeletal myogenesis in vivo. Development. 2015;142:2405–2412. doi: 10.1242/dev.123026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Santoyo-Ramos P, Likhatcheva M, Garcia-Zepeda EA, Castaneda-Patlan MC, Robles-Flores M. Hypoxia-inducible factors modulate the stemness and malignancy of colon cancer cells by playing opposite roles in canonical Wnt signaling. PLoS ONE. 2014;9:e112580. doi: 10.1371/journal.pone.0112580. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Zhong Z, et al. Wntless functions in mature osteoblasts to regulate bone mass. Proc. Natl Acad. Sci. USA. 2012;109:E2197–E2204. doi: 10.1073/pnas.1120407109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Olsen JJ, et al. The role of Wnt signalling in angiogenesis. Clin. Biochem Rev. 2017;38:131–142. [PMC free article] [PubMed] [Google Scholar]
- 30.Rosenstein JM, Krum JM, Ruhrberg C. VEGF in the nervous system. Organogenesis. 2010;6:107–114. doi: 10.4161/org.6.2.11687. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Mancuso MR, Kuhnert F, Kuo CJ. Developmental angiogenesis of the central nervous system. Lymphat Res Biol. 2008;6:173–180. doi: 10.1089/lrb.2008.1014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Sondell M, Sundler F, Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur. J. Neurosci. 2000;12:4243–4254. doi: 10.1046/j.0953-816X.2000.01326.x. [DOI] [PubMed] [Google Scholar]
- 33.Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J. Neurosci. 1999;19:5731–5740. doi: 10.1523/JNEUROSCI.19-14-05731.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Namiecinska M, Marciniak K, Nowak JZ. VEGF as an angiogenic, neurotrophic, and neuroprotective factor. Postepy Hig. Med Dosw (Online) 2005;59:573–583. [PubMed] [Google Scholar]
- 35.Sun Y, et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J. Clin. Invest. 2003;111:1843–1851. doi: 10.1172/JCI200317977. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Hayakawa K, et al. Vascular endothelial growth factor regulates the migration of oligodendrocyte precursor cells. J. Neurosci. 2011;31:10666–10670. doi: 10.1523/JNEUROSCI.1944-11.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Arai K, Lo EH. An oligovascular niche: cerebral endothelial cells promote the survival and proliferation of oligodendrocyte precursor cells. J. Neurosci. 2009;29:4351–4355. doi: 10.1523/JNEUROSCI.0035-09.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Arai K, Jin G, Navaratna D, Lo EH. Brain angiogenesis in developmental and pathological processes: neurovascular injury and angiogenic recovery after stroke. FEBS J. 2009;276:4644–4652. doi: 10.1111/j.1742-4658.2009.07176.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Stone J, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J. Neurosci. 1995;15:4738–4747. doi: 10.1523/JNEUROSCI.15-07-04738.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Komatsu DE, Hadjiargyrou M. Activation of the transcription factor HIF-1 and its target genes, VEGF, HO-1, iNOS, during fracture repair. Bone. 2004;34:680–688. doi: 10.1016/j.bone.2003.12.024. [DOI] [PubMed] [Google Scholar]
- 41.Nordal RA, Nagy A, Pintilie M, Wong CS. Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clin. Cancer Res. 2004;10:3342–3353. doi: 10.1158/1078-0432.CCR-03-0426. [DOI] [PubMed] [Google Scholar]
- 42.Cheng L, Yu H, Yan N, Lai K, Xiang M. Hypoxia-inducible factor-1alpha target genes contribute to retinal neuroprotection. Front Cell Neurosci. 2017;11:20. doi: 10.3389/fncel.2017.00020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Stefater JA, 3rd, et al. Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature. 2011;474:511–515. doi: 10.1038/nature10085. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Clifford RL, Deacon K, Knox AJ. Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor (beta)1: requirement for Smads, (beta)-CATENIN, AND GSK3(beta) J. Biol. Chem. 2008;283:35337–35353. doi: 10.1074/jbc.M803342200. [DOI] [PubMed] [Google Scholar]
- 45.Wu C, et al. Wnt/beta-catenin coupled with HIF-1alpha/VEGF signaling pathways involved in galangin neurovascular unit protection from focal cerebral ischemia. Sci. Rep. 2015;5:16151. doi: 10.1038/srep16151. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Fancy SP, et al. Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nat. Neurosci. 2011;14:1009–1016. doi: 10.1038/nn.2855. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Fancy, S. P. et al. Parallel states of pathological Wnt signaling in neonatal brain injury and colon cancer. Nat Neurosci, 10.1038/nn.3676nn.3676[pii] (2014). [DOI] [PMC free article] [PubMed]
- 48.Ye F, et al. HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat. Neurosci. 2009;12:829–838. doi: 10.1038/nn.2333. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Feigenson K, Reid M, See J, Crenshaw EB, 3rd, Grinspan JB. Wnt signaling is sufficient to perturb oligodendrocyte maturation. Mol. Cell Neurosci. 2009;42:255–265. doi: 10.1016/j.mcn.2009.07.010. [DOI] [PubMed] [Google Scholar]
- 50.Zeis T, Graumann U, Reynolds R, Schaeren-Wiemers N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain. 2008;131:288–303. doi: 10.1093/brain/awm291. [DOI] [PubMed] [Google Scholar]
- 51.Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol. 2003;13:554–573. doi: 10.1111/j.1750-3639.2003.tb00485.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Lassmann H, et al. A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions. Brain. 2003;126:1347–1357. doi: 10.1093/brain/awg127. [DOI] [PubMed] [Google Scholar]
- 53.Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J. Neurol. Sci. 2003;206:187–191. doi: 10.1016/S0022-510X(02)00421-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Gerber HP, et al. VEGF is required for growth and survival in neonatal mice. Development. 1999;126:1149–1159. doi: 10.1242/dev.126.6.1149. [DOI] [PubMed] [Google Scholar]
- 55.Weidemann A, et al. The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice. J. Clin. Invest. 2009;119:3373–3383. doi: 10.1172/JCI39378. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Zhang, S. et al. Sox2 is essential for oligodendroglial proliferation and differentiation during postnatal brain myelination and CNS remyelination. J Neurosci. 10.1523/JNEUROSCI.1291-17.2018 (2018). [DOI] [PMC free article] [PubMed]
- 57.Zhang, S. et al. The stem cell factor Sox2 Is a positive timer of oligodendrocyte development in the postnatal murine spinal cord. Mol. Neurobiol. 10.1007/s12035-018-1035-7 (2018). [DOI] [PMC free article] [PubMed]
- 58.Guo F, et al. Disruption of NMDA receptors in oligodendroglial lineage cells does not alter their susceptibility to experimental autoimmune encephalomyelitis or their normal development. J. Neurosci. 2012;32:639–645. doi: 10.1523/JNEUROSCI.4073-11.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The source data underlying Figs. 1b, c, e–m, 2a–k, 3b–d, 4c–f, h, j, k, l, 5c–f, 6a–c, f–i, 7a–g, 8c, d, f–g, 9a, b, d, e, g, h, 10b, d, Supplementary Figs. 3b–d, 4c, f, g, 6, 7b, 8a, b, 9b, c, 10a–d, 11b, 12b, c, e, f, 13b are provided as a Source Data file. The data that support this study are available from the corresponding author upon reasonable request.